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Abstract We previously isolated the human RPB11 cDNA,
encoding the 13.3 kDa subunit of RNA polymerase II, and
demonstrated that expression of this subunit is modulated by
doxorubicin. Using hRPB11 as bait in a yeast two-hybrid system,
two cDNA variants encoding a second RNA polymerase II
subunit, hRPB3, have now been isolated and characterized.
These two hRPB3 mRNA species differed in 3P UTR region
length, the longer transcript containing the AU-rich sequence
motif that mediates mRNA degradation. Both hRPB11 and
hRPB3 transcripts share a similar pattern of distribution in
human adult tissues, with particularly high levels in both heart
and skeletal muscle, and the expression of both is down-regulated
by doxorubicin as found previously for the hRPB11 subunit.
Taken together, these findings suggest that the interaction
between hRPB3 and hRPB11 is fundamental for their function
and that this heterodimer is involved in doxorubicin toxicity.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Doxorubicin (dox) is an antineoplastic antibiotic with a
broad spectrum of chemotherapeutic activity on several hu-
man malignancies [1]. However, its clinical use is often limited
because of serious cumulative dose-dependent cardiac toxicity
[2] and multidrug resistance. In fact several tumors do not
respond to the cytotoxic activity of the drug and/or become
resistant to treatment after an initial response [3,4].
In a previous study, we used di¡erential display polymerase
chain reaction to identify potential novel molecular mecha-
nisms involved in doxorubicin toxicity and isolated a gene,
the expression of which was down-regulated in doxorubicin-
resistant human carcinoma cell lines [5]. This gene encoded
the human RNA polymerase II (pol II) subunit hRPB11 [5^7].
Treatment of cells with dox down-modulated the expression
of this RNA polymerase II subunit at both the mRNA and
protein levels [5]. Messenger RNA for hRPB11 was expressed
ubiquitously in all normal tissues tested, with highest expres-
sion in heart and skeletal muscle, in which the highest toxicity
to dox was observed.
Eukaryotic RNA pol II is composed of more than 12 poly-
peptides ranging from 220 to 10 kDa [8]. The RPB1, RPB2
and RPB3 subunits are structural homologues of the Esche-
richia coli RNA polymerase core subunits LP, L and K, respec-
tively. The minimum and essential subunits required for eu-
karyotic mRNA synthesis, however, remain to be elucidated.
Although the function of the smaller subunits is not yet com-
pletely understood, evidence suggests that yeast RNA pol II
may in£uence gene expression by altering its subunit compo-
sition in response to stress [9,10]. As hRPB11 is modulated by
dox treatment, we used this pol II subunit as bait in the yeast
two-hybrid system to identify potential interaction-target pro-
tein(s), in an e¡ort to clarify its functions.
We report the characterization of two cDNA variants en-
coding the hRPB3 subunit of RNA pol II, and con¢rm their
interaction with hRPB11 in the yeast two-hybrid system.
Moreover, we demonstrate coordinate hRPB11 and hRPB3
expression in adult human tissues and coordinate repression
of expression following dox treatment.
2. Materials and methods
2.1. Yeast two-hybrid selection
The cDNA of hRPB11 modi¢ed for sub-cloning in frame with the
GAL4 binding domain (BD) was prepared and inserted into the PstI
restriction site of vector pGBT9 (Clontech, Palo Alto, CA). The yeast
strain HF7c [11], bearing UASg-His3 and UASg-LacZ as reporter
genes, was cotransformed with the bait PGBT9-hRPB11 and a library
prepared with human skeletal muscle cDNA fused to the GAL4 acti-
vation domain (AD), in the vector pGad10 (Clontech). Transforma-
tion was performed using the lithium acetate method [12]. Cells were
plated directly on minimal synthetic de¢ned medium (SD): 2% glu-
cose, 0.67% Bacto yeast nitrogen base (Difco), supplemented with the
required bases and amino acids [13], lacking leucine (Leu), tryptophan
(Trp), and histidine (His). Plates were incubated for 7 days at 30‡C
and His transformants isolated. The His colonies, replica-plated on
SD-Leu-Trp-His medium and LacZ, were identi¢ed by a ¢lter-lifting
assay for L-galactosidase activity [13]. Plasmid DNA was prepared
from candidate clones and electroporated into E. coli XLI-blue com-
petent cells (Stratagene, La Jolla, CA). The recovered library-derived
plasmids were further analyzed as positive candidates. To investigate
the hRPB11 domains involved in the selected interactions, three new
baits were constructed in the pGBT9 vector. These three constructs
carried di¡erent hRPB11 deletions: 11Qui (from aa 24 to aa 117),
11Quo (from aa 54 to aa 117), 11Qua (from aa 87 to aa 117).
2.2. Coimmunoprecipitation
The hRPB11 and hRPB3 cDNAs were modi¢ed for sub-cloning in
frame in mammalian expression vectors pEGFP-N1 (Clontech) and
pcDNA3.1/Myc-His (Invitrogen, Carlsbad, CA), respectively. COS7
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cells (American Type Culture Collection) were cultured to approxi-
mately 70% con£uence in 10 cm diameter dishes, and transfected
using the calcium phosphate procedure [14], with either CMV-myc-
tag vector or CMV-myc-tag-hRPB3 and CMV-GFP-hRPB11. After
36 h of incubation at 5% CO2, cells were rinsed three times with ice-
cold PBS, harvested, centrifuged at 4‡C, and cell pellets lysed by
incubation at 4‡C for 1 h in 400 Wl of lysis bu¡er (100 mM NaCl,
1% NP-40, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.02% NaN3,
1 mM PMSF, 10 mg/ml leupeptin). Lysates were centrifuged in an
Eppendorf centrifuge (top speed, 4‡C for 5 min). Supernatants recov-
ered were incubated with a monoclonal anti-myc antibody (Invitro-
gen) for 1 h at 4‡C, followed by addition of 20 Wl of protein A/G
PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) and in-
cubation for an additional 2 h. The resins were then washed three
times in the same bu¡er, the bound proteins were separated by re-
ducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) [15].
Proteins were transferred to nitrocellulose (Amersham, Bucks., UK)
and membranes probed with a monoclonal anti-GFP antibody (Clon-
tech). Immunoreactivity was detected using an enhanced chemilumi-
nescence kit (Amersham) as described by the manufacturer.
2.3. DNA sequencing
All constructs reported were sequenced by Sequenase reaction
(Amersham) according to the manufacturer’s instructions.
2.4. Cell lines and drug treatment
Human colon carcinoma LoVo H dox-sensitive and LoVo DX dox-
resistant cells were kindly provided by Dr. M.P. Colombo (Istituto
Nazionale Tumori, Milan, Italy). Establishment and characteristics of
these cells have been described elsewhere [16]. LoVo DX cells were
maintained in continuous exposure to 0.2 WM dox (Adriblastina,
Farmitalia Carlo Erba, Milan, Italy).
2.5. RNA extraction and northern blotting analysis
Total RNA was extracted from dox-resistant and dox-sensitive hu-
man LoVo cell lines, as described by Chomczynski and Sacchi [17].
20 Wg of total RNA was separated by 1.2% agarose-formaldehyde gel
electrophoresis and transferred to nylon ¢lters (Hybond-N, Amer-
sham) [14]. Pre-made ¢lters containing poly(A) RNA from eight
normal human tissues (MNT human blot I) were purchased from
Clontech. Blots were hybridized using Quikhyb (Stratagene), accord-
ing to the manufacturer’s instructions. 32P-labelled cDNA probes were
prepared using a Megaprime probe kit (Amersham). Quantitative
loading of RNA was determined by hybridization with a glyceralde-




In order to investigate potential protein/protein interactions
driven by hRPB11, screening of a yeast two-hybrid system
was performed using the complete cDNA coding sequence
for hRPB11 fused to the Gal4 binding domain of the plasmid
vector pGBT9. Because of the high level of transcription of
the hRPB11 gene in human skeletal muscle, a cDNA library
prepared from this tissue and incorporated in the plasmid
vector pGAD10 was used. Using the appropriate yeast report-
er strain, 1U106 clones were screened, and clones exhibiting a
positive interaction were further analyzed. Eight clones inter-
acting strongly with the bait were isolated (Fig. 1B), and all
encoded a second human RNA polymerase II subunit
‘hRPB3’ [19], adding to recent reports of a similar interaction
in humans, mice and Arabidopsis [20^22]. Both hRPB11 and
hRPB3 subunits exhibited limited amino acid sequence ho-
mology to the K-subunit of E. coli RNA polymerase. This
region, termed the ‘K-like domain’, suggests that hRPB11/3
heterodimers may be considered the eukaryotic counterpart
of the bacterial K-subunit homodimer [23,24]. Since the inter-
action between hRPB11 and hRPB3 directly involves the
K-like domain of the hRPB3 protein [22], we examined
whether the K-like domain of hRPB11 was involved. For
this purpose hRPB3 subunits containing three di¡erent ami-
no-terminal deletions of hRPB11, 11Qui, 11Quo, 11Qua re-
spectively, were screened in the yeast two-hybrid system
(Fig. 1A). Only the deletion 11Qui retained the ability to
interact with the hRPB3 subunit, indicating that a minimal
region of 30 amino acid containing the K-like domain was
essential (Fig. 1B).
3.2. hRPB11 interacts with hRPB3 in vivo
To establish whether hRPB11 interacted with the hRPB3
subunit in mammalian cells, GFP-hRPB11 and myc-tag-
FEBS 20197 7-5-98
Fig. 1. A: Schematic diagrams of N-terminal deletions of the
hRPB11 RNA polymerase II subunit. B: Demonstration of the in-
teraction between hRPB3 and hRPB11 N-terminal deletions by His3
assay. The SV40LT/p53 interaction was been used a positive con-
trol.
Fig. 2. Western blot analysis of GFP-hRPB11 fusion protein recov-
ered from immunoprecipitates of transfected COS7 whole cell ex-
tracts using anti-myc antibody. In each case 20% of input extract
(INPUT) shown.
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hRPB3 fusion proteins were overexpressed in COS7 cells. Fig.
2 demonstrates Western blot analysis using a monoclonal
anti-GFP antibody. In total lysates a protein of 41 kDa, con-
sistent with the size of the GFP-hRPB11 fusion protein, was
present. GFP-hRPB11 was also detected in immunoprecipi-
tates of myc-hRPB3, indicating physical interaction between
hRPB3 and hRPB11 subunits within mammalian cells.
3.3. Two cDNA variants encoded for the hRPB3 subunit of
RNA polymerase II
Fig. 3 shows two cDNA variants encoding the hRPB3 sub-
unit of RNA pol II, previously described by Pati and Weiss-
man [19]. The two variants were independently cloned, six and
two times, respectively. DNA sequence analysis of the clones
demonstrated that all encode a complete hRPB3 protein and
di¡er only in the length of the 3P UTR region. The shorter
and the longer variants were named hRPB3K and hRPB3L,
respectively. Interestingly, both variants di¡ered in the same
region from the longer transcript described by Pati and Weiss-
man [19]. The hRPB3L transcript terminated with a canonical
polyadenylation signal and contained in the 3P UTR region an
AU-rich sequence motif, which mediates mRNA degradation
[25] (Fig. 3). The hRPB3K transcript terminated earlier than
the L type with a canonical polyadenylation signal, lacking the
AU-rich sequence as a result of alternative splicing.
3.4. hRPB3 and hRPB11 share the same pattern of tissue
expression
Since hRPB11 and hRPB3 RNA polymerase II subunits
interact, we investigated whether they share the same pattern
of tissue distribution. The expression of hRPB3 mRNA was
analyzed by Northern blot using poly(A) selected RNA pre-
pared from eight normal tissues. As shown in Fig. 4, two
mRNA species were detected exhibiting sizes consistent with
those of hRPB3K and L variants. The intensity of the hybrid-
ization signal for hRPB3K mRNA was greater than hRPB3L.
hRPB3 transcripts were found in all tissues analyzed, but they
peaked in heart, muscle and pancreas. These results clearly
demonstrate that hRPB3 shares the same tissue distribution
as described for hRPB11 [5].
3.5. Doxorubicin down-regulates the expression of hRPB3
It has been previously demonstrated that doxorubicin
down-regulates the expression of the hRPB11 RNA pol II
subunit [5]. We therefore examined the e¡ects of dox on
hRPB3 transcription. Fig. 5A shows that both hRPB3K and
L variants were highly expressed in the dox-sensitive cell line
LoVo H, but barely detectable in dox-resistant LoVo DX
cells. This demonstrates the sensitivity of both subunits to
dox. To better de¢ne the role of dox in the regulation of
hRPB3, expression was analyzed in LoVo DX cells after the
complete withdrawal of dox from the culture medium. This
resulted in the gradual increase in hRPB3 mRNA levels (Fig.
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Fig. 5. A (top): Northern blot analysis of hRPB3 subunit expres-
sion using total RNA puri¢ed from the dox-sensitive human cell
line (LoVo H) and the dox-resistant cell line (LoVo DX). B (top):
LoVo DX cells cultured in the absence of doxorubicin; numbers in-
dicate weeks of cell growth in culture medium without dox. The ab-
sence of the drug induced a gradual up-modulation of hRPB3
mRNA levels, which after 3 weeks reached the levels observed in
the LoVo H cell line. The amount of RNA loaded in each lane was
normalized by the hybridization signals obtained using as a probe
GAPDH (A and B, bottom).
Fig. 4. Expression analysis of hRPB3 by Northern blot analysis of
poly(A) RNA puri¢ed from eight di¡erent adult human tissues.
The hybridization signals, corresponding to the mRNA variants
hRPB3L and hRPB3K, are indicated by arrows.
Fig. 3. Nucleotide and amino acid sequences of two hRPB3 cDNA
variants (hRPB3K and hRPB3L) encoding a human subunit of
RNA polymerase II. Nucleotides are numbered on the right in bold
characters, amino acid residues are numbered on the right. Both the
hRPB3K and L transcripts encode a complete hRPB3 protein, but
di¡er in the length of the 3P UTR region. Starting from the diver-
gent nucleotide in position 1379, the two cDNA variants follow in-
dependent nucleotide numeration, indicated by two arrows: u for
hRPB3L and s for hRPB3K. The polyadenylation consensus signals
present in both cDNAs are underlined. The AU-rich sequence motif
that mediates mRNA degradation in hRPB3K cDNA is underlined
and indicated by italic characters. The hRPB3K and hRPBL nucleo-
tide sequences have been deposited in GenBank with accession num-
bers AJ224143 and AJ224144, respectively.
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5B), which reached those in the LoVo H cell line after 3 weeks
(Fig. 5A). This con¢rmed a direct correlation between doxo-
rubicin toxicity and the expression of components of the
hRPB11/3 complex.
4. Discussion
Doxorubicin exhibits speci¢c and systemic toxic e¡ects
through several mechanisms including generation of oxygen
free radicals [26], interaction with cell membrane constituents
[27], and induction of large gene deletions in mammalian cells
[28]. A selective action on several genes has also been re-
ported, suggesting that this drug may exert speci¢c e¡ects
on the transcriptional machinery. In particular, a down-mod-
ulation of mRNA levels has been described for di¡erent
muscle-speci¢c genes [29]. Interestingly, the transcriptional ac-
tivity of RNA polymerase II, in a crude preparation, is in-
hibited by doxorubicin [30]. Further investigation of the
mechanisms involved in dox toxicity has identi¢ed a core sub-
assembly subunit of RNA polymerase II, hRPB11, speci¢cally
a¡ected by doxorubicin administration [5]. This subunit was
used as bait to screen a yeast two-hybrid system to identify
potential protein/protein interactions. We report that hRPB11
interacts with a second RNA polymerase II subunit, named
hRPB3. hRPB3 was the only RNA polymerase II partner/
component isolated, supporting the hypothesis that the
hRPB3 subunit is a unique partner for hRPB11 in RNA pol
II [20]. The interaction between hRPB11 and hRPB3 subunits
has been recently reported in mouse, human and Arabidopsis
thaliana [20^22], and the K-like domain of hRPB3 was shown
to be essential for this interaction [22]. Here, we demonstrate
that the K-like domain of hRPB11 is also involved in this
interaction, consistent with the prominent role of this domain
in RNA polymerase function and its high degree of evolu-
tionary conservation. Indeed, these two subunits have been
recently shown to form the core subassembly subunit of
RNA pol II [31]. This is reminiscent of the K2L complex of
E. coli RNA polymerase, which is an intermediate subassem-
bly in the following pathway: KCK2CK2LCK2LLI [32]. All
of these observations underscore a fundamental structure role
of this heterodimer.
On the other hand, our data suggest a putative regulatory
role for these subunits. Analysis of hRPB3 and hRPB11 tran-
scription revealed coordinated tissue expression. Although es-
sential for cellular viability [33], and despite the fact that tran-
scripts were detected in all adult tissues analyzed, both
subunits exhibited modulated expression with clear peaks in
heart and muscle tissues, which exhibit the highest responses
to dox. Furthermore, hRPB3 and hRPB11 [5] expression was
strongly down-regulated in dox-resistant LoVo cells and re-
versed by drug withdrawal.
The necessity for ¢ne regulation of hRPB3 expression was
also underlined by the isolation of two mRNA variants, dif-
fering in the UTR region for an AU-rich mRNA degradation
motif [25]. Interestingly, the longer transcript was expressed
several fold higher than the other variant, but was more sen-
sitive to the e¡ects of dox. In fact, in dox-resistant LoVo cells
the hRPB3L variant was only slightly detectable.
Further support for a putative regulative role for hRPB3 in
the transcription comes from the observation that the cjnC
gene product, a homologue of hRPB3 in Tetrahymena, is
only active during early conjugation, suggesting that it may
be involved in the regulation of transcription at that partic-
ular time [34]. Moreover, computer analysis of hRPB3 protein
has revealed several putative functional domains including the
RNA polymerase K-like motif, an EF-hand calcium-binding
domain at position aa 136^148 [35], and a cysteine reach
region resembling a potential zinc-¢nger motif in position aa
88^115 [22].
All these considerations support a putative regulative role
of hRPB3 subunit, and additional studies will be required to
better characterize its functions.
Acknowledgements: We acknowledge Dr. Andrew McKay for critical
reading. Miss Roberta Bruno is gratefully acknowledged for artwork.
This work was partially supported by Ministero della SanitaØ, Telethon
Project A63, and MURST 60%.
References
[1] Young, R.C., Ozols, R.F. and Myers, C.E. (1981) New Engl.
J. Med. 305, 153^158.
[2] Singal, P.K., Deally, C.M. and Weimberg, L.E. (1987) J. Mol.
Cell. Cardiol. 19, 817^828.
[3] Ueda, K., Cardarelli, C., Gottesman, M.M. and Pastan, I. (1987)
Proc. Natl. Acad. Sci. USA 84, 3004^3008.
[4] Grant, C.E., Valdimarsson, G., Hipfner, D.R., Almquist, K.C.,
Cole, S.P. and Deely, R.G. (1994) Cancer Res. 54, 357^361.
[5] Fanciulli, M., Bruno, T., Cerboni, C., Bonetto, F., Iacobini, C.,
Frati, L., Piccoli, M., Floridi, A., Santoni, A. and Punturieri, A.
(1996) FEBS Lett. 384, 48^52.
[6] Woychik, N.A., McKune, K., Lane, W.S. and Young, R.A.
(1993) Gene Express. 3, 77^82.
[7] Pati, U.K. (1994) Gene 145, 289^292.
[8] Young, R.A. (1991) Annu. Rev. Biochem. 60, 689^715.
[9] Choder, M. and Young, R.A. (1993) Mol. Cell. Biol. 13, 6984^
6991.
[10] Woychik, N.A., Lane, W.S. and Young, R.A. (1991) J. Biol.
Chem. 266, 19053^19055.
[11] Feilotter, H.E., Hannon, G.J., Ruddel, C.J. and Beach, D. (1994)
Nucleic Acids Res. 22, 1502^1503.
[12] Gietz, D., St. Jean, A., Woods, R.A. and Schiestl, R.H. (1992)
Nucleic Acids Res. 20, 1425^1426.
[13] Guthrie, C. and Fink, G.R. (1991) Methods Enzymol. 194, 1^
932.
[14] Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Labora-
tory, Cold Spring Harbor, NY.
[15] Laemmli, U.K. (1970) Nature 227, 680^685.
[16] Li-Ying, Y. and Trujillo, J.M. (1990) Cancer Res. 50, 3218^3225.
[17] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156^
159.
[18] Piechaczyk, M., Blanchard, J.M., Marty, L., Dani, C., Pana-
bieres, F., El Sabouty, S., Fort, P. and Jeanteur, P. (1984) Nu-
cleic Acids Res. 12, 6951^6963.
[19] Pati, U.K. and Weissman, S.M. (1990) J. Biol. Chem. 265, 8400^
8403.
[20] Acker, J., de Graa¡, M., Cheynel, I., Khazak, V., Kedinger, C.
and Vigneron, M. (1997) J. Biol. Chem. 272, 16815^16821.
[21] Nishi, Y., Yamamoto, K., Yao, Y., Yamamoto, M., Nogi, Y.,
Matsuo, H. and Muramatsu, M. (1997) Gene 187, 165^170.
[22] Ulmasov, T., Larkin, R.M. and Guilfoyle, T.J. (1996) J. Biol.
Chem. 271, 5085^5094.
[23] Woychik, N.A., McKune, K., Lane, W.S. and Young, R.A.
(1993) Gene Express. 3, 77^82.
[24] Pati, U.K. (1994) Gene 145, 289^292.
[25] Zubiaga, A.M., Belasco, J.G. and Greenberg, M.E. (1995) Mol.
Cell. Biol. 15, 2219^2230.
[26] Doroshow, J.H. (1983) Cancer Res. 43, 460^472.
[27] Siegfried, J.A., Kennedy, K.A., Sartorelli, A.C. and Tritton, T.R.
(1983) J. Biol. Chem. 258, 339^345.
[28] Yu, Y., Xu, Z. and Hsie, A.W. (1994) Mutat. Res. 325, 91^98.
[29] Ito, H., Miller, S.C., Billingham, M.E., Akimoto, H., Torti, S.V.,
FEBS 20197 7-5-98
M. Fanciulli et al./FEBS Letters 427 (1998) 236^240 239
Wade, R., Gahlmann, R., Lyons, G., Kedes, L. and Torti, F.M.
(1990) Proc. Natl. Acad. Sci. USA 87, 4275^4279.
[30] Chuang, R.Y. and Chuang, L.F. (1979) Biochemistry 18, 2069^
2073.
[31] Kimura, M., Ishiguro, A. and Ishihama, A. (1997) J. Biol. Chem.
272, 25851^25855.
[32] Ishihama, A. (1981) Adv. Biophys. 14, 1^35.
[33] Kolodziej, P. and Young, R.A. (1989) Mol. Cell Biol. 9, 5387^
5394.
[34] Martindale, D.W. (1990) Nucleic Acids Res. 18, 2953^2960.
[35] Kawasaki, H. and Kretsinger, R.H. (1995) Protein Prof. 2, 305^
490.
FEBS 20197 7-5-98
M. Fanciulli et al./FEBS Letters 427 (1998) 236^240240
